CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
CymaBay Therapeutics SG&A Expense (Annual): 51.95M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 51.95M |
| December 31, 2022 | 25.12M |
| December 31, 2021 | 23.04M |
| December 31, 2020 | 16.72M |
| December 31, 2019 | 19.24M |
| December 31, 2018 | 14.38M |
| Date | Value |
|---|---|
| December 31, 2017 | 12.39M |
| December 31, 2016 | 9.645M |
| December 31, 2015 | 8.871M |
| December 31, 2014 | 8.185M |
| December 31, 2013 | 4.871M |
| December 31, 2012 | 4.208M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
16.72M
Minimum
2020
51.95M
Maximum
2023
27.21M
Average
23.04M
Median
2021
SG&A Expense (Annual) Benchmarks
| Gilead Sciences Inc | 6.09B |
| Assure Holdings Corp | 13.52M |
| Societal CDMO Inc (DELISTED) | 21.02M |
| AN2 Therapeutics Inc | 14.76M |
| Madrigal Pharmaceuticals Inc | 108.15M |